<DOC>
	<DOCNO>NCT00258063</DOCNO>
	<brief_summary>The objective study estimate exposure hormone norelgestromin , norgestrel , ethinyl estradiol healthy female volunteer across multiple commercial lot EVRAÂ® ( transdermal contraceptive patch manufacture LOHMANN Therapie-Systeme ) , compare data exposure data one clinical lot , compare data exposure data commercially available oral contraceptive .</brief_summary>
	<brief_title>A Study Evaluate Exposure Norelgestromin Ethinyl Estradiol From Commercial Lots EVRA ( Transdermal Contraceptive Patch Manufactured LOHMANN Therapie-Systeme ) CILEST ( Oral Contraceptive )</brief_title>
	<detailed_description>This single-center , open-label , randomize , partially-balanced , incomplete block design study consist pre-treatment phase ( screening period last 21 day ) , open-label treatment phase ( three 7-day treatment period separate 21-day washout ) , post-treatment phase ( follow-up early withdrawal visit ) . Total participation study approximately 67 day . Approximately 54 subject enrol . The study population comprise healthy woman , age 18 45 year inclusive , weigh least 110 pound , body mass index ( BMI ) 16 29.9 kg per meter square . Subjects wear EVRA® patch take CILEST® three 7-day treatment period ; treatment period separate 21-day washout period . When subject wear EVRA® , patch 1 6 select commercial lot apply buttock worn 7 day . Patches apply investigator designate study unit personnel . All patch wear upper outer quadrant buttock , necessarily exact position . The investigator designate study unit personnel remove patch evaluate adhesion patch removal . When subject receive CILEST® , tablets 1 3 select commercial lot administer daily 7 consecutive day . A minimum 21 day removal patch seventh dose CILEST® , subject begin another treatment period , complete 3 open-label treatment period . Subjects confine study unit blood sample collection determination NGMN , NG , EE plasma concentration . Blood sample collect ( via venipuncture ) immediately dose specified time point dose administer . Pharmacokinetic parameter NGMN , NG , EE , include Cmax , tmax , AUC , treatment estimate standard method . Safety assess throughout study , base adverse event change physical gynecologic examination ( include breast examination ) , vital sign , electrocardiogram ( ECGs ) , clinical laboratory test result . Three 7-day treatment period ; treatment separate 21-day washout . Based randomization schedule , subject wear EVRA® patch 3 period ( upper outer quadrant buttock 7 day ) , wear patch 2 period take CILEST® oral tablet daily 1 period , wear patch 1 period take CILEST® oral tablet daily 2 period .</detailed_description>
	<mesh_term>Norelgestromin</mesh_term>
	<mesh_term>Ortho Evra</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<mesh_term>Norgestrel</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<criteria>Subjects pregnant ( demonstrated negative pregnancy test screen admission treatment period ) complete last term pregnancy least 60 day admission visit confirm good health determine medical history , physical examination ( include vital sign ) , gynecologic examination ( include breast examination ) , laboratory test result history regular menstrual cycle , weigh least 110 pound ( 50 kilogram ) , body mass index ( BMI ) 16 29.9 kg per meter square , hematocrit least 36 % screening , ferritin level lower limit normal nonsmoker use tobacco product least 6 month study admission agree use prescription nonprescription medication duration study , subject male partner surgically sterile , agree continue use nonhormonecontaining intrauterine device ( IUD ) one follow method doublebarrier contraception participation study : condom foam , diaphragm gel , cervical cap gel . Subjects history presence disorder commonly accept contraindication sex hormonal therapy include , limited : deep vein thrombophlebitis thromboembolic disorder , cerebral vascular coronary artery disease , chronic untreated hypertension migraine , benign malignant liver tumor develop use oral contraceptive estrogencontaining product , know suspected estrogendependent neoplasia presence disorder commonly accept contraindication combine oral contraceptive therapy include , limited : undiagnosed abnormal vaginal bleeding , neurovascular lesion eye serious visual disturbance , impairment liver function , liver disease , kidney disease currently pregnant breast feeding , evidence cervical dysplasia ( document Pap smear within 6 month randomization ) use steroid hormonal therapy within 30 day first admission visit , receive Depo Provera® injection within 6 month first admission visit , receive Lunelle® injection within 60 day first admission visit , currently Norplant® place , removal Norplant within 60 day first admission visit , use steroid hormonecontaining intrauterine device ( IUD ) within 3 month randomization elevate blood pressure ( sit systolic BP &gt; 140 mm Hg and/or diastolic BP &gt; 90 mm Hg ) history presence hypersensitivity response topical application ( bandage , surgical tape , etc . ) active inflammation skin ( dermatitis ) skin condition ( dermatosis ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Transdermal contraception</keyword>
	<keyword>contraceptive</keyword>
	<keyword>hormonal , steroid contraception</keyword>
	<keyword>ethinyl estradiol</keyword>
	<keyword>progesterone</keyword>
	<keyword>EVRA</keyword>
	<keyword>CILEST</keyword>
	<keyword>ORTHO EVRA</keyword>
</DOC>